Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Benzinga · 10/14 16:09
Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $6 price target.